Skip to main content

A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.

Publication ,  Journal Article
Assouline, S; Michaelis, LC; Othus, M; Hay, AE; Walter, RB; Jacoby, MA; Schroeder, MA; Uy, GL; Law, LY; Cheema, F; Sweet, KL; Asch, AS ...
Published in: Leuk Lymphoma
February 2023

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Leuk Lymphoma

DOI

EISSN

1029-2403

Publication Date

February 2023

Volume

64

Issue

2

Start / End Page

473 / 477

Location

United States

Related Subject Headings

  • Nivolumab
  • Myelodysplastic Syndromes
  • Middle Aged
  • Leukemia, Myelomonocytic, Chronic
  • Leukemia, Myeloid, Acute
  • Immunology
  • Humans
  • Azacitidine
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Assouline, Sarit, Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby, Mark A. Schroeder, et al. “A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.Leuk Lymphoma 64, no. 2 (February 2023): 473–77. https://doi.org/10.1080/10428194.2022.2148212.
Assouline S, Michaelis LC, Othus M, Hay AE, Walter RB, Jacoby MA, Schroeder MA, Uy GL, Law LY, Cheema F, Sweet KL, Asch AS, Liu JJ, Moseley AB, Maher T, Kingsbury LL, Fang M, Radich J, Little RF, Erba HP. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leuk Lymphoma. 2023 Feb;64(2):473–477.

Published In

Leuk Lymphoma

DOI

EISSN

1029-2403

Publication Date

February 2023

Volume

64

Issue

2

Start / End Page

473 / 477

Location

United States

Related Subject Headings

  • Nivolumab
  • Myelodysplastic Syndromes
  • Middle Aged
  • Leukemia, Myelomonocytic, Chronic
  • Leukemia, Myeloid, Acute
  • Immunology
  • Humans
  • Azacitidine
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences